BIOFLUIDICA, INC.
Chapel Hill, NC · Founded 2013 · CIK 0001670738 · Medtech · Private
Microfluidic platform for isolating circulating fetal trophoblast cells from maternal blood for non-invasive prenatal testing
biofluidica.com →- Grants
- $6.7M
- 14 awards
- Sector median: 1
- Raised
- $13M
- 5 Form D · Dec 2021
- 58 months since last filing
- Contracts
- $1.2M
- 2 awards · Health and Human S
- #295 of 4531 in medtech
- Patents
- 12
- 3 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · TAS::75 0849::TAS | $199,517 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf R&d- Medical: Biomedical (basic Research) | $990,380 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · CTC Screening Assay to Address Health Disparities in Women with Ovarian Cancer | $199,848 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · CTC Screening Assay to Address Health Disparities in Women with Ovarian Cancer | $399,681 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs) | $808,983 | |
| Private capital raised | Form D · SEC | $1,079,999 | |
| Federal grant | Department of Health and Human Services · Phase I · CTC Screening Assay to Address Health Disparities in Women with Ovarian Cancer | $199,833 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs) | $687,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood | $798,225 | |
| Private capital raised | Form D · SEC | $4,135,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood | $712,071 | |
| Federal grant | Department of Health and Human Services · Phase I · Parallel and high throughput isolation of cancer cell derived extracellular vesicles | $239,138 | |
| Federal grant | Department of Health and Human Services · Phase II · Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia | $348,768 | |
| Private capital raised | Form D · SEC | $1,058,813 | |
| Federal grant | Department of Health and Human Services · Phase I · Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms | $286,548 | |
| Federal grant | Department of Health and Human Services · Phase I · A microfluidic platform for the high-throughput isolation circulating fetal trophoblasts for non-invasive prenatal testing | $291,545 | |
| Federal grant | Department of Health and Human Services · Phase I · A microfluidic platform for the high-throughput isolation circulating fetal trophoblasts for non-invasive prenatal testing | $291,545 | |
| Federal grant | Department of Health and Human Services · Phase II · Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia | $837,994 | |
| Private capital raised | Form D · SEC | $3,096,566 | |
| Federal grant | Department of Health and Human Services · Phase II · Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia | $556,708 | |
| Private capital raised | Form D · SEC | $3,537,700 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 292 | CIVATECH ONCOLOGY, INC. | $1.2M | $12M |
| 293 | CLEAR GUIDE MEDICAL, INC. | $1.2M | $25K |
| 294 | CLEAR GUIDE MEDICAL, LLC | $1.2M | $3.6M |
| 295 | BIOFLUIDICA, INC. | $1.2M | $13M |
| 296 | Paragon 28, Inc. | $1.2M | $50K |
| 297 | WICAB, INC | $1.2M | $3.4M |
| 298 | HYPOTHERMIA DEVICES INC | $1.2M | $11M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Philip BuchananDirector
- PHILIP BUCHANANDirector
- Rolf MullerDirector · Executive Officer
- ROLF MULLERDirector · Executive Officer
- Judy Muller-CohnExecutive Officer
- JUDY MULLER-COHNExecutive Officer
- Steven SoperDirector · Executive Officer
- STEVEN SOPERDirector · Executive Officer
- Michael StocumDirector
- MICHAEL STOCUMDirector
- Sam TetlowDirector · Executive Officer
Patents
- Methods Of Isolating Biomarker Cellsgranted
- Dual-Depth Thermoplastic Microfluidic Device and Related Systems and Methodsgranted
- Dual-Depth Thermoplastic Microfluidic Device and Related Systems and Methodsgranted
- High Efficiency Capture of Fetal Cells from Maternal Samples; and Whole Blood Buffer Compositions and Related Methodsapplication
- Fluid-tight Flow System To Isolate Biomarkers From A Liquid Sampleapplication
- Dual-Depth Thermoplastic Microfluidic Device and Related Systems and Methodsapplication
- Fluid-tight Flow System To Isolate Biomarkers From A Liquid Sampleapplication
- Fluid-tight Flow System To Isolate Biomarkers From A Liquid Sampleapplication
- Whole Blood Buffer Composition and Related Methods Eliminating Microclotting and Aggregation for Microfluidic Applicationsapplication
- High Efficiency Capture Of Fetal Cells From Maternal Samplesapplication
- Dual-depth Thermoplastic Microfluidic Device And Related Systems And Methodsapplication
- High Efficiency Capture of Fetal Cells from Maternal Samplesapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.